All In Biotech

Drug Trial Radar · NCT00129298

Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1

Tiagabine for the Treatment of Cocaine Dependence in Methadone-Maintained Individuals

Last checked: Nov 19, 2026Latest source record: Jan 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Dec 2004

Primary completion

Not stated

Study completion Apr 2007

Sponsor

Sponsor type
NIH
First posted
Aug 11, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many opioid-dependent individuals are also dependent on cocaine. Methadone is a widely used and effective method for treating opioid dependence. However, it is not effective in treating other drugs of abuse. The purpose of this study is to determine the effectiveness of another drug, tiagabine, for treating cocaine dependence in opioid-dependent individuals already receiving methadone treatment.

Conditions

  • Cocaine-Related Disorders
  • Opiate Dependence

Interventions

  • TiagabineDrug

    The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Thrice weekly Urine toxicologyTime frame: 13 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.